Targeted Therapy with Anti-EGFR and Anti-VEGF Therapy and Beyond

Christine M. Parseghian; Alisha H. Bent

doi:10.1007/978-3-031-09323-4_33

Targeted Therapy with Anti-EGFR and Anti-VEGF Therapy and Beyond

Christine M. Parseghian, Alisha H. Bent

GI Medical Oncology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Despite multiple available systemic treatment options, overall survival (OS) of metastatic CRC (mCRC) remains poor (5-year OS < 20%). A deeper understanding of the pathways implicated in cancer cell proliferation has allowed for the development of innovative treatment strategies in patients with mCRC. Targeted therapies such as BRAF inhibitors for patients with BRAF V600E mutations, anti-EGFR therapies for patients without RAS mutations, and immunotherapy for patients with microsatellite unstable tumors have been shown to improve outcomes in biomarker-selected patients with mCRC. This chapter reviews our current understanding of targeted therapy in the management of mCRC with a focus on inhibitors of EGFR and angiogenesis, and other multikinase inhibitors.

Original language	English (US)
Title of host publication	Colorectal Liver Metastasis
Publisher	Springer International Publishing
Pages	293-299
Number of pages	7
ISBN (Electronic)	9783031093234
ISBN (Print)	9783031093227
DOIs	https://doi.org/10.1007/978-3-031-09323-4_33
State	Published - Jan 1 2022

Keywords

Anti-EGFR therapy
Anti-VEGF therapy
BRAF inhibitors
Microsatellite instability
Targeted therapy

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-3-031-09323-4_33

Cite this

@inbook{93295a5ec32248a98ccb429b580650c1,

title = "Targeted Therapy with Anti-EGFR and Anti-VEGF Therapy and Beyond",

abstract = "Despite multiple available systemic treatment options, overall survival (OS) of metastatic CRC (mCRC) remains poor (5-year OS < 20%). A deeper understanding of the pathways implicated in cancer cell proliferation has allowed for the development of innovative treatment strategies in patients with mCRC. Targeted therapies such as BRAF inhibitors for patients with BRAF V600E mutations, anti-EGFR therapies for patients without RAS mutations, and immunotherapy for patients with microsatellite unstable tumors have been shown to improve outcomes in biomarker-selected patients with mCRC. This chapter reviews our current understanding of targeted therapy in the management of mCRC with a focus on inhibitors of EGFR and angiogenesis, and other multikinase inhibitors.",

keywords = "Anti-EGFR therapy, Anti-VEGF therapy, BRAF inhibitors, Microsatellite instability, Targeted therapy",

author = "Parseghian, {Christine M.} and Bent, {Alisha H.}",

note = "Publisher Copyright: {\textcopyright} The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022.",

year = "2022",

month = jan,

day = "1",

doi = "10.1007/978-3-031-09323-4_33",

language = "English (US)",

isbn = "9783031093227",

pages = "293--299",

booktitle = "Colorectal Liver Metastasis",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Targeted Therapy with Anti-EGFR and Anti-VEGF Therapy and Beyond

AU - Parseghian, Christine M.

AU - Bent, Alisha H.

N1 - Publisher Copyright: © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022.

PY - 2022/1/1

Y1 - 2022/1/1

N2 - Despite multiple available systemic treatment options, overall survival (OS) of metastatic CRC (mCRC) remains poor (5-year OS < 20%). A deeper understanding of the pathways implicated in cancer cell proliferation has allowed for the development of innovative treatment strategies in patients with mCRC. Targeted therapies such as BRAF inhibitors for patients with BRAF V600E mutations, anti-EGFR therapies for patients without RAS mutations, and immunotherapy for patients with microsatellite unstable tumors have been shown to improve outcomes in biomarker-selected patients with mCRC. This chapter reviews our current understanding of targeted therapy in the management of mCRC with a focus on inhibitors of EGFR and angiogenesis, and other multikinase inhibitors.

AB - Despite multiple available systemic treatment options, overall survival (OS) of metastatic CRC (mCRC) remains poor (5-year OS < 20%). A deeper understanding of the pathways implicated in cancer cell proliferation has allowed for the development of innovative treatment strategies in patients with mCRC. Targeted therapies such as BRAF inhibitors for patients with BRAF V600E mutations, anti-EGFR therapies for patients without RAS mutations, and immunotherapy for patients with microsatellite unstable tumors have been shown to improve outcomes in biomarker-selected patients with mCRC. This chapter reviews our current understanding of targeted therapy in the management of mCRC with a focus on inhibitors of EGFR and angiogenesis, and other multikinase inhibitors.

KW - Anti-EGFR therapy

KW - Anti-VEGF therapy

KW - BRAF inhibitors

KW - Microsatellite instability

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85158946584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85158946584&partnerID=8YFLogxK

U2 - 10.1007/978-3-031-09323-4_33

DO - 10.1007/978-3-031-09323-4_33

M3 - Chapter

AN - SCOPUS:85158946584

SN - 9783031093227

SP - 293

EP - 299

BT - Colorectal Liver Metastasis

PB - Springer International Publishing

ER -

Targeted Therapy with Anti-EGFR and Anti-VEGF Therapy and Beyond

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this